美泊利单抗联合或不联合FESS对重度CRSwNP患者睡眠及OSA的影响:一项随机对照试验
本研究为58例重度未控制CRSwNP患者的随机试验,比较美泊利单抗单用或联合FESS对睡眠质量与OSA的影响。结果显示两组睡眠质量主观指标均显著改善,但客观OSA指标(AHI、ODI)无显著变化。
要点
- 美泊利单抗联合或不联合FESS可改善CRSwNP患者主观睡眠质量与疲劳。
- 治疗未显著改变OSA客观严重程度(AHI、ODI)。
- 基线70%患者合并OSA,34.6%为中重度OSA。
核心结论
- 美泊利单抗联合或不联合FESS可改善重度未控制CRSwNP患者的主观睡眠质量并减轻疲劳,但未显著影响OSA严重程度。
研究设计与样本
- 随机对照试验,纳入58例重度未控制CRSwNP患者,接受美泊利单抗单用或联合FESS治疗。
主要发现
- 基线时70%的参与者存在OSA(AHI ≥5),34.6%为中重度OSA。
- 治疗6个月后,两组睡眠质量主观指标(SNOT-22、FOSQ-10、ESS)均显著改善。
- 客观OSA指标(AHI、ODI)无显著变化;OSA患者严重程度有所降低但无统计学意义。
- 随访期间无严重不良事件(SAE)。
临床怎么用
- 对于重度未控制CRSwNP合并OSA的患者,美泊利单抗联合或不联合FESS可改善主观睡眠质量,但不应期望其显著改善OSA客观指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) often leads to poor sleep quality and fatigue. Many patients with CRSwNP are also at risk for obstructive sleep apnea (OSA). This study examined how mepolizumab and/or endoscopic sinus surgery (FESS) affect sleep quality and OSA in patients with severe uncontrolled CRSwNP. METHODS: In a randomised trial with 58 patients, participants received mepolizumab alone or combined with FESS. Sleep quality was measured using FOSQ-10 and ESS, and OSA severity via AHI from home sleep apnea tests. RESULTS: At baseline, 70% of participants had OSA (AHI ≥5), with 34.6% having moderate-to-severe OSA. After six months, there were significant improvements in sleep quality (SNOT-22, FOSQ-10, ESS) in both groups but no significant change in objective OSA measures (AHI, ODI). Patients with OSA showed a reduction in severity, however non-significant. There were no severe adverse events (SAE) during the follow-up. CONCLUSIONS: Mepolizumab, with or without FESS, improved subjective sleep quality and reduced fatigue but did not significantly affect OSA severity. This suggests that while treatment eases sleep-related symptoms, it may not resolve underlying OSA, particularly in more severe cases.
引用
- Homoe AS, Kiaer EK, Aanaes K, et al. Improving sleep in severe CRSwNP: an RCT on the effect of mepolizumab and FESS on OSA, sleep disturbances and quality of life. Rhinology. 2026. PMID: 41051759. doi:10.4193/Rhin25.228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。